MX2020006284A - Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson. - Google Patents

Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson.

Info

Publication number
MX2020006284A
MX2020006284A MX2020006284A MX2020006284A MX2020006284A MX 2020006284 A MX2020006284 A MX 2020006284A MX 2020006284 A MX2020006284 A MX 2020006284A MX 2020006284 A MX2020006284 A MX 2020006284A MX 2020006284 A MX2020006284 A MX 2020006284A
Authority
MX
Mexico
Prior art keywords
bis
choline tetrathiomolybdate
methods
wilson disease
treating wilson
Prior art date
Application number
MX2020006284A
Other languages
English (en)
Inventor
Carl Bjartmar
Karl-Heinz Weiss
Michael Schilsky
Frederick Askari
Anna Czlonkowska
Peter Ferenci
Peter Hedera
Aftab Ala
Original Assignee
Alexion Pharma Int Operations Unlimited Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Int Operations Unlimited Company filed Critical Alexion Pharma Int Operations Unlimited Company
Publication of MX2020006284A publication Critical patent/MX2020006284A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se proporcionan métodos para tratar la enfermedad de Wilson con terapia de tetratiomolibdato de bis-colina. Los métodos pueden incluir administrar 15 mg o entre 30 y 90 mg de tetratiomolibdato de bis-colina una vez al día a un paciente que exhibe niveles de NCC corregido, alanina aminotransferasa (ALT), hemoglobina, plaquetas o neutrófilos que cumplen criterios establecidos. Los métodos pueden incluir modificar el tratamiento al disminuir o aumentar la dosis diaria de tetratiomolibdato de bis-colina o discontinuar el tratamiento por un período de tiempo.
MX2020006284A 2017-12-04 2018-12-04 Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson. MX2020006284A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762594184P 2017-12-04 2017-12-04
US201862646553P 2018-03-22 2018-03-22
US201862655568P 2018-04-10 2018-04-10
US201862669095P 2018-05-09 2018-05-09
US201862741313P 2018-10-04 2018-10-04
US201862750595P 2018-10-25 2018-10-25
PCT/EP2018/083551 WO2019110619A1 (en) 2017-12-04 2018-12-04 Bis-choline tetrathiomolybdate for treating wilson disease

Publications (1)

Publication Number Publication Date
MX2020006284A true MX2020006284A (es) 2021-04-12

Family

ID=64661349

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006284A MX2020006284A (es) 2017-12-04 2018-12-04 Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson.

Country Status (16)

Country Link
US (3) US11510944B2 (es)
EP (2) EP4029498A1 (es)
JP (2) JP2021505655A (es)
KR (1) KR20200096798A (es)
AU (1) AU2018379255A1 (es)
BR (1) BR112020011055A2 (es)
CA (1) CA3084100A1 (es)
DK (1) DK3720433T3 (es)
ES (1) ES2912306T3 (es)
HU (1) HUE058921T2 (es)
IL (1) IL275115A (es)
MX (1) MX2020006284A (es)
PL (1) PL3720433T3 (es)
PT (1) PT3720433T (es)
SI (1) SI3720433T1 (es)
WO (1) WO2019110619A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3720433T (pt) * 2017-12-04 2022-05-03 Alexion Pharma Inc Tetratiomolibdato de bis-colina para tratar a doença de wilson
US11419832B2 (en) * 2017-12-04 2022-08-23 Alexion Pharmaceuticals, Inc. Bis-choline tetrathiomolybdate for treating Wilson Disease
EP3749417A1 (en) 2018-02-06 2020-12-16 Alexion Pharma International Operations Unlimited Company Crystalline particles of bis-choline tetrathiomolybdate
WO2021102379A1 (en) 2019-11-21 2021-05-27 Alexion Pharmaceuticals, Inc. Methods of reducing neurological damage in wilson disease patients
EP4243806A1 (en) 2020-11-13 2023-09-20 Alexion Pharmaceuticals, Inc. Methods of treating copper metabolism-associated diseases or disorders
US20240100088A1 (en) * 2021-01-31 2024-03-28 Alexion Pharmaceuticals, Inc. Novel formulation for treating copper metabolism-associated diseases or disorders
CA3228221A1 (en) 2021-08-17 2023-02-23 Brian Meltzer Methods of treating copper metabolism-associated diseases or disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189865B2 (en) * 2002-07-23 2007-03-13 Attenuon, Llc Thiomolybdate analogues and uses thereof
KR20050025976A (ko) * 2002-07-23 2005-03-14 더 리젠츠 오브 더 유니버시티 오브 미시건 항-혈관형성 치료법에 사용하기 위한 테트라프로필암모늄테트라티오몰리브데이트 및 관련 화합물
JP2009523175A (ja) 2006-01-10 2009-06-18 パイペックス，インコーポレイテッド 目標とされる安定な銅状態を達成及び維持して銅関連中枢神経系疾患を予防及び治療するための医薬組成物及び方法
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
PT3720433T (pt) 2017-12-04 2022-05-03 Alexion Pharma Inc Tetratiomolibdato de bis-colina para tratar a doença de wilson
US11419832B2 (en) * 2017-12-04 2022-08-23 Alexion Pharmaceuticals, Inc. Bis-choline tetrathiomolybdate for treating Wilson Disease
EP3749417A1 (en) 2018-02-06 2020-12-16 Alexion Pharma International Operations Unlimited Company Crystalline particles of bis-choline tetrathiomolybdate

Also Published As

Publication number Publication date
CA3084100A1 (en) 2019-06-13
EP4029498A1 (en) 2022-07-20
US20230070534A1 (en) 2023-03-09
US11510944B2 (en) 2022-11-29
EP3720433A1 (en) 2020-10-14
JP2023075247A (ja) 2023-05-30
ES2912306T3 (es) 2022-05-25
WO2019110619A1 (en) 2019-06-13
PT3720433T (pt) 2022-05-03
US20210137972A1 (en) 2021-05-13
JP2021505655A (ja) 2021-02-18
AU2018379255A1 (en) 2020-06-25
SI3720433T1 (sl) 2022-09-30
PL3720433T3 (pl) 2022-07-18
KR20200096798A (ko) 2020-08-13
IL275115A (en) 2020-07-30
RU2020122023A (ru) 2022-01-10
DK3720433T3 (da) 2022-05-02
US20210177894A1 (en) 2021-06-17
BR112020011055A2 (pt) 2020-11-17
EP3720433B1 (en) 2022-02-02
HUE058921T2 (hu) 2022-09-28

Similar Documents

Publication Publication Date Title
MX2020006284A (es) Tetratiomolibdato de bis-colina para tratar la enfermedad de wilson.
MX2022004137A (es) Metodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
MX2023012450A (es) Esketamina para el tratamiento de la depresion.
CL2018001677A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
MX2023005455A (es) Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil.
AU2018326364A1 (en) Methods of enhancing and/or stabilizing cardiac function in patients with Fabry disease
MX2016009231A (es) Administracion de tasimelteon en condiciones de ayuno.
PH12017500392A1 (en) Medical treatments based on anamorelin
PH12021550047A1 (en) USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS
MX2016016400A (es) Formulaciones de oximetazolina estabilizadas y sus usos.
MX2021009413A (es) Materiales y métodos para tratar una enfermedad neurodegenerativa.
MX2021008986A (es) Metodos de tratamiento de un paciente con enfermedad de parkinson.
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
MX2019004200A (es) Terapia de combinacion.
MX2019008076A (es) Regimen terapeutico para el tratamiento de fabry usando alfa-galactosidasa estabilizada.
WO2017189906A8 (en) Immune-based treatment of kras-variant cancer patients
AU2020360413A8 (en) Methods of treating conditions related to the S1P1 receptor
MX2022003628A (es) Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente.
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
EP4245366A3 (en) Migalastat for treating fabry patients having renal impairment
AR111971A1 (es) Métodos para tratar pacientes con enfermedad de fabry que tienen insuficiencia renal
MX2022002947A (es) Avocatina b para el tratamiento de enfermedades y afecciones.
UA127590U (uk) Спосіб лікування хворих на псоріаз
MDS20160124U2 (ro) Metodă de profilaxie a limforeii prolongate în tratamentul radical al cancerului glandei mamare la pacientele cu diabet zaharat tip 2
Fabiny Ask the doctor. I recently took antibiotics to treat an oral infection and as a result developed a vaginal yeast infection. Can I treat it myself, and what are the most effective options?